PROCARDIA XL
Pronunciation: nye-FED-i-peen


What it isNifedipine GITS extended-release (PROCARDIA XL, 1989) blocks L-type calcium channels; hypertension and stable or vasospastic angina.
Why this oneThe once-daily osmotic tablet avoids the rapid peaks, reflex tachycardia and pressure swings of immediate-release nifedipine.
What limits itPeripheral edema often ends treatment; headache, flushing, and reflex tachycardia reflect vasodilation.
Principal riskReflex tachycardia and peripheral edema
Legacy pregnancy categoryC
Defining liabilityHypotension and reflex tachycardia; overdose can cause severe vasodilatory shock.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Hypertension | Adults | 30 or 60 mg QD | Individualized (titrate over 7–14 days) | Titration above 120 mg/day not recommended |
| Vasospastic angina | Adults | 30 or 60 mg QD | Individualized (titrate over 7–14 days) | Above 120 mg/day not recommended; doses >90 mg limited experience in angina — use with caution |
| Chronic stable (effort-associated) angina | Adults symptomatic despite or intolerant of beta blockers and/or nitrates | 30 or 60 mg QD | Individualized (titrate over 7–14 days) | Above 120 mg/day not recommended; doses >90 mg limited experience in angina — use with caution |
| Angina — switch from nifedipine capsules | Adults controlled on IR nifedipine capsules | Nearest equivalent total daily dose QD (e.g., 10 mg TID capsules → 30 mg QD) | Retitrate as clinically warranted | Above 120 mg/day not recommended |
Titration Generally over 7–14 days; may proceed faster (steady state on day 2) if symptoms warrant and patient assessed frequently
Renal No adjustment stated; PK not significantly influenced by renal impairment (rare reversible BUN/creatinine rises in chronic renal insufficiency)
Hepatic No specific dose given; cirrhosis prolongs half-life and raises bioavailability — use caution
Food slightly alters early absorption but not extent (no labeled empty-stomach requirement); GI obstruction/bezoar risk with strictures or GI narrowing
Available strengths
Pregnancy Teratogenic and embryo-/fetotoxic in animals; no adequate human studies — use only if potential benefit justifies potential risk.
Lactation Nifedipine is transferred into breast milk; use during breast-feeding only if potential benefit justifies potential risk.
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 30 mg | ER tab | 30 qd | $3.90 | offered |
| 60 mg | ER tab | 30 qd | $5.04 | offered |
| 90 mg | ER tab | 30 qd | $8.07 | offered |
Other forms: Nifedipine (PROCARDIA)
Open Nifedipine ER (GITS) in the interactive console ↗

Open Nifedipine ER (GITS) in the interactive console ↗